Ubs Asset Management Americas Inc Morphic Holding, Inc. Transaction History

Ubs Asset Management Americas Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$26.12 - $34.07 $700,198 - $913,314	26,807 Added 134.84%	46,688 $1.59 Million
Q4 2023 Feb 14, 2024	BUY	$19.95 - $31.0 $158,143 - $245,737	7,927 Added 66.31%	19,881 $574,000
Q3 2023 Nov 13, 2023	SELL	$21.33 - $59.42 $35,365 - $98,518	-1,658 Reduced 12.18%	11,954 $273,000
Q1 2023 May 15, 2023	BUY	$26.01 - $48.69 $354,048 - $662,768	13,612 New	13,612 $512,000
Q2 2022 Aug 12, 2022	SELL	$19.74 - $43.01 $231,510 - $504,421	-11,728 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$45.13 - $64.99 $56,096 - $80,782	1,243 Added 11.86%	11,728 $673,000
Q1 2021 May 14, 2021	BUY	$29.77 - $84.85 $312,138 - $889,652	10,485 New	10,485 $663,000

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.